Cronos Stock Quote Today

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:3em;padding-top: 38px;;'>CRO</div>
Cronos is selling for 6.32 as of the 12th of July 2020. This is 4.98% increase since the beginning of the trading day. The stock's open price was 6.02. Cronos has 47 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 30 trading days. Equity ratings for Cronos Group Inc are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 13th of April 2020 and ending today, the 12th of July 2020. Click here to learn more.
Analyze Filter   Report: 6th of August 2020

3 100 

   Odds of Distress

Cronos Profile

The upcoming quarterly report is expected on the 6th of August 2020. Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. Its brand portfolio includes PEACE NATURALS, a global wellness platform adult-use brands comprise COVE and Spinach and hemp-derived CBD brands consists of Lord Jones and PEACE. Cronos operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 631 people. more on Cronos
Cronos Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Cronos Group Common SEC Filings
Cronos SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameCronos Group Inc
ChairmanMichael GorensteinView All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Cronos Group Common. The Cronos consensus assessment is calculated by taking the average estimates from all of the analysts covering Cronos
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Cronos Group Common financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 4 - OrdinaryDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares244.9 M310.1 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted245.5 M310.1 M
Significantly Down
Slightly volatile
Net Cash Flow from Operations(133.4 M)(130 M)
Fairly Down
Slightly volatile
Total Assets2.3 B2.1 B
Significantly Up
Slightly volatile
Total Liabilities368.4 M341.4 M
Significantly Up
Slightly volatile
Current Assets1.7 B1.6 B
Significantly Up
Slightly volatile
Current Liabilities359.2 M332.9 M
Significantly Up
Slightly volatile
Total Debt7.7 M7.1 M
Significantly Up
Slightly volatile
Return on Average Assets0.610.56
Significantly Up
Slightly volatile
Gross Margin(0.7718)(0.752)
Fairly Down
Slightly volatile
Asset Turnover0.01130.011
Fairly Up
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cronos available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong SellOvervalued
Financial Strength
Cronos financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cronos success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
Cronos Group Inc (CRON) is traded on BATS Exchange in USA. It is located in 720 King Street West and employs 631 people. Cronos is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cronos's market, we take the total number of its shares issued and multiply it by Cronos's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cronos Group Common conducts business under Healthcare sector and is part of Drug Manufacturers?Specialty & Generic industry. The entity has 348.82 M outstanding shares of which 48.01 M shares are currently shorted by private and institutional investors with about 5.41 trading days to cover. The company currently holds about 1.33 B in cash with (155.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.83.
Check Cronos Probability Of Bankruptcy

Ownership Allocation (%)

Cronos Stock Price Odds Analysis

Odds Down 6.32HorizonTargetOdds Up 6.32
61.09%30 days
Based on a normal probability distribution, the odds of Cronos to move above the current price in 30 days from now is about 38.75 (This Cronos Group Inc probability density function shows the probability of Cronos Stock to fall within a particular range of prices over 30 days) .

Cronos Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares10.1 M57.4 M
Chescapmanager LlcCommon Shares8.9 M50.3 M
Susquehanna International Group LlpCall Options4.6 M26.1 M
Susquehanna International Group LlpPut Options3.3 M18.5 M
View Cronos Diagnostics

Cronos Income Statement Over Time

Cronos Group Inc Income Statement is one of the three primary financial statements used for reporting Cronos's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cronos Group Common revenue and expense. Cronos Income Statement primarily focuses on the company's revenues and expenses during a particular period. Cronos Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at about 111.8 Million. Revenues is projected to rise to about 25.6 M this year, although the value of Gross Profit will most likely fall to (18.3 M). View More Fundamentals

Cronos Stock Against Markets

Did you try this?

Run Financial Widgets Now


Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Cronos Upcoming and Recent Events

Cronos Company Earnings Announcements Dates

Upcoming Quarterly Report6th of August 2020
Next Earnings Report10th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End29th of March 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Cronos Corporate Filings

Cronos SEC Reporting

Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cronos Corporate Directors

Bruce Gates Director
Jason Adler Director
Michael Krestell Independent Director
Continue to Trending Equities. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page